Loading...
Please wait, while we are loading the content...
Similar Documents
Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib
| Content Provider | SAGE Publishing |
|---|---|
| Author | Mahuad, Carolina Valeria María de los Ángeles Vicente Repáraz Zerga, Marta E. Aizpurua, María Florencia Casali, Claudia Garate, Gonzalo |
| Copyright Year | 2016 |
| Abstract | The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gene. The reported cases describe the use of crizotinib as a bridging strategy prior to allotransplantation; there are no reported prolonged survivals under monotherapy with Crizotinib. We report a case of a primary refractory ALK+ anaplastic large-cell lymphoma that sustains complete response after 3 years of crizotinib monotherapy. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.4081/rt.2016.6266?download=true |
| Starting Page | 88 |
| Ending Page | 89 |
| Page Count | 2 |
| ISSN | 20363613 |
| Issue Number | 2 |
| Volume Number | 8 |
| Journal | Rare Tumors (RTU) |
| e-ISSN | 20363613 |
| DOI | 10.4081/rt.2016.6266 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2016-06-01 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © 2016 SAGE Publications. |
| Subject Keyword | anaplastic lymphoma kinase anaplastic crizotinib Lymphoma large-cell |
| Content Type | Text |
| Resource Type | Article |
| Subject | Histology Oncology |
